The TheraCyte^™ System

The TheraCyte™ system is protected by 20 U.S. patents and multiple foreign patents and patent filings in Europe and Japan. The company has a substantial database demonstrating biocompatibility and protection of allografts using the TheraCyte™ system in rodents, rabbits, dogs, primates, and humans. The device is effective for many months and does not require immune-suppressive drugs. Tests for up to one year in humans have shown absolute biocompatibility, immune protection, and secretion of a therapeutic protein (parathyroid hormone) from TheraCyte™ devices containing allogeneic tissue.

Devices were well tolerated in these studies and were easily removed at the end of the study. The breadth and effectiveness of the TheraCyte™ cell delivery platform has been shown by a large number of animal studies using a wide variety of therapeutic agents. TheraCyte™ has been used to correct diabetes in rodents and deliver molecules such as Human Growth Hormone, cytokines, monoclonal antibodies and erythropoietin using genetically engineered cells.